In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

BioPlan Associates presents research and projections on the pharma sterile fill-finish industry’s future over the next 10 ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA ...

Regeneron Pharmaceuticals, Inc. obtained a positive opinion for its pipeline candidate, linvoseltamab, from the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

"Always amazing to win an ICC event. I remember 2017 very closely, couldn't finish that time. Very pleased to have done it here," Hardik, who contributed significantly to India's title triumph on ...

Current approaches to pain relief are falling short. Chemically modifying a synthetic cannabinoid could enable scientists to capitalize on the body’s natural pain-killing pathway without evoking ...